DAVID LASKOW-POOLEY JOINS BOARD OF TESTAVEC LTD
David Laskow- Pooley has joined the company to accelerate the commercialisation of the science developed by Professor Themis.
Historically David has worked for companies as varied as Life Technologies, now part of Thermo Fisher Scientific and Amersham Pharmacia Biotech, now part of Cytivia, in addition to pharmaceutical companies, GSK, Abbive, and OSI Pharmaceuticals. He was on the Council of Oxford Brookes University and founded an independent company specialising in the spin-out and building of entities, principally in technologies resulting from academic research.
Commenting on Laskow-Pooley’s appointment Robert Spencer, Chairman of TestAVec said “ Gene therapy and CAR-T therapy have the possibility to bring enormous benefits to humanity as recent publicity has shown, but there are risks attached to these kind of Therapies that need to be reduced- TestAVec has the science to do this and I am delighted David has decide to join us and to accelerate the commercialisation of TestAVec’s technology.
Commenting on his appointment David said “having had a very varied career around medical science I was fascinated by the TestAVec technology and could see its importance – I am delighted I can bring my experience to help develop this exciting young company’s services.
Comments